-Results from Part A of Phase 3 study in people with a mutation that results in minimal cystic fibrosis transmembrane conductance regulator (CFTR) protein function do not support continuation of the ...

Vertex ( ($VERX) ) has shared an update. On October 30, 2025, Vertex‘s Board of Directors authorized a stock repurchase program for up to $150 ...

Vertex has stopped development of VX-961 after getting a look at phase 1 data. The NaV1.8 inhibitor failed to meet Vertex’s desired pharmacokinetic and tolerability profile, leading it to dump the ...

- Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...

Vertex Announces Initiation of Pivotal Phase 3 Program of VX-809 in Combination with Ivacaftor for the Treatment of People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation -Global ...

- Phase 2 data demonstrated that a once-daily triple combination of VX-121/ tezacaftor/VX-561 has potential for enhanced clinical benefit compared to TRIKAFTA ...

-Mean absolute improvement in ppFEV 1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo (p<0.0001) in patients with one F508del mutation and one minimal function ...

--Results to be shared with health authorities in order to identify the most rapid path forward -- CAMBRIDGE, Mass., Mar 27, 2008 -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced ...

Vertex Submits Application for Priority Review and Approval of KALYDECO TM (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis -- Accelerated ...

Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has lifted the clinical hold placed on the phase I/II study evaluating its investigational stem cell-based therapy, VX-880, for the ...